P/E at 38.63 vs Industry's 37.11: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Sector Confidence

The current P/E of Sun Pharmaceutical Industries Ltd stands at 38.63, slightly above the Pharmaceuticals & Biotechnology industry average of 37.11. This premium, though not excessive, signals that investors are willing to pay a higher multiple relative to peers, potentially reflecting confidence in the company’s earnings stability and growth prospects. The market capitalisation of Rs 4,82,506.26 crore places it firmly in the large-cap category, underscoring its dominant position within the sector.

Such a valuation premium often invites scrutiny — Sun Pharmaceutical Industries Ltd trades at approximately 1.04 times the sector P/E, which is a narrower gap than seen in some other large-cap pharmaceuticals. This suggests a valuation that is broadly in line with sector fundamentals rather than a speculative premium. Sun Pharma’s P/E premium may also be supported by its consistent earnings delivery and market leadership.

Performance Across Timeframes: Sustained Outperformance

Examining the stock’s returns reveals a strong performance relative to the Sensex across multiple timeframes. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 17.91% gain, contrasting with the Sensex’s 3.97% decline. This outperformance extends to shorter intervals as well: a 3-month return of 11.22% versus the Sensex’s 1.37%, and a 1-month return of 7.77% compared to the benchmark’s 1.36%. Year-to-date, the stock has appreciated 16.94%, while the Sensex has fallen 8.51%.

Such consistent alpha generation suggests robust underlying business momentum. The stock’s 5-day consecutive gain streak, with a 4.06% rise, further highlights recent positive sentiment. The 1-day gain of 0.51% also outpaces the Sensex’s 0.05% increase, indicating ongoing buying interest. Sun Pharma’s ability to sustain gains across multiple horizons raises the question — is this momentum likely to continue or is the stock approaching a technical resistance?

Moving Average Configuration: Bullish Technical Setup

The technical picture for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This alignment is often interpreted as a strong bullish signal, indicating that the stock is in an established uptrend across short, medium, and long-term timeframes.

Trading above the 200-day moving average is particularly significant, as it suggests that the stock has overcome longer-term resistance levels. The fact that the stock hit a new 52-week and all-time high of Rs 2019.8 today further reinforces this positive technical momentum. The 5-day and 20-day averages provide support for near-term price action, while the 50-day and 100-day averages confirm sustained strength. The 200-day average acts as a key psychological and technical benchmark for institutional investors.

This comprehensive moving average configuration supports the view that the recent gains are not merely a short-term bounce but part of a broader trend. However, does this technical strength justify a reassessment of the stock’s rating, or is caution warranted given the valuation premium?

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed but Positive Results

The Pharmaceuticals & Biotechnology sector has seen a generally positive set of results recently. Out of eight stocks that declared results, five reported positive outcomes, two were flat, and one was negative. This sector-wide performance backdrop provides a supportive environment for Sun Pharmaceutical Industries Ltd, which has outperformed many peers in terms of price appreciation.

The sector’s mixed results highlight the importance of stock-specific factors in driving performance. Sun Pharma’s ability to outperform the sector and the Sensex across multiple timeframes suggests that company-specific fundamentals and technicals are playing a decisive role. This raises the question — how does the stock’s updated rating reflect these sector dynamics and its relative strength?

Rating Context: Previously Rated Hold, Now Reassessed

On 8 June 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating assigned by MarketsMOJO. While the current rating is not disclosed, the reassessment coincides with the stock’s strong performance and technical breakout. The Mojo Score of 72.0 reflects a solid overall assessment, balancing valuation, financial trends, and technical factors.

The rating update suggests a reconsideration of the stock’s prospects in light of recent data. The valuation premium, sustained outperformance, and bullish moving average configuration collectively provide a compelling data-driven rationale for this reassessment. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Conclusion: Data Reflects a Balanced but Positive Outlook

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight valuation premium, supported by consistent outperformance across short and long-term horizons. The bullish moving average configuration and recent all-time high reinforce the technical strength underpinning the stock’s gains.

Sector results are broadly positive, and the stock’s Mojo Score of 72.0 alongside a recent rating reassessment from Hold indicates a fresh evaluation of its prospects. While the premium valuation invites caution, the sustained momentum and technical signals suggest that the stock is in a favourable phase. is this the right time to adjust exposure to Sun Pharmaceutical Industries Ltd?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →